Free Trial
NASDAQ:LSTA

Lisata Therapeutics Q4 2025 Earnings Report

Lisata Therapeutics logo
$3.23 +0.03 (+1.06%)
As of 10:03 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Lisata Therapeutics EPS Results

Actual EPS
-$0.33
Consensus EPS
-$0.74
Beat/Miss
Beat by +$0.41
One Year Ago EPS
N/A

Lisata Therapeutics Revenue Results

Actual Revenue
$0.10 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lisata Therapeutics Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Lisata Therapeutics' next earnings date is estimated for Thursday, August 6, 2026, based on past reporting schedules.

Earnings Documents

Lisata Therapeutics Earnings Headlines

SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
See More Lisata Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lisata Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lisata Therapeutics and other key companies, straight to your email.

About Lisata Therapeutics

Lisata Therapeutics (NASDAQ:LSTA) (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies. To advance its programs, the company collaborates with academic institutions and contract research organizations, supporting clinical studies and translational research efforts in North America and Europe.

Headquartered in the United States, Lisata Therapeutics is governed by a leadership team with experience in biotechnology research, clinical operations and regulatory affairs. The company’s board and scientific advisors bring expertise in immunology, drug development and commercial strategy to support its mission of addressing unmet medical needs.

View Lisata Therapeutics Profile